

Clinical application of drug screening in circulating tumor cells in patients with breast cancers

Submission date 04/08/2024	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 29/08/2024	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 29/08/2024	Condition category Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Breast cancer is the leading cancer death for women worldwide, and the mortality rate is still high although several clinical drugs have been developed within this decade. Therapeutic failure results in tumor recurrence and metastasis is still a major challenge for clinicians and researchers. Circulating tumor cells (CTCs) are rare cells (1 CTCs/10⁶ hematopoietic cells) in the peripheral blood that usually remain undetected by clinically used high-resolution imaging technologies. However, drug screening of CTCs for therapeutic purposes remains to be explored. This study aims to investigate the clinical impact of CTCs either in drug screening or survival of patients with breast cancer.

Who can participate?

Female newly diagnosed primary locally advanced breast cancer patients enrolled in Linkou Chang Gung Memorial Hospital

What does the study involve?

Participants were scheduled to receive either systemic treatment including chemotherapy, immunotherapy, target therapy or endocrine therapy for their tumors for CTC enumeration. A sample of primary tumor tissue was also taken for an immunohistochemistry study for correlation of the result of CTCs including the relationship of immune cells and tumor cells. The outcome of the patients will be evaluated including the clinical and pathological response of the treatment, time to progression and the follow-up time will be up to 3 years.

What are the possible benefits and risks of participating?

The study results do not influence the treatment option, so there is no direct benefit for clinical outcome but the study will provide prognostic information from the disease.

This is an observational study that does not contain any risk to the participants.

Where is the study run from?

Linkou Chang Gung Memorial Hospital (Taiwan)

When is the study starting and how long is it expected to run for?
March 2020 to July 2023

Who is funding the study?
Chang Gung Medical Foundation (Taiwan)

Who is the main contact?
Hsu-Huan Chou (Principal Investigator), b9002009@cgmh.org.tw

Contact information

Type(s)

Public, Scientific, Principal Investigator

Contact name

Mr Hsu-Huan Chou

ORCID ID

<http://orcid.org/0000-0002-0948-1141>

Contact details

4F., No. 15, Aly. 7, Ln. 240, Sec. 3, Roosevelt Rd., Zhongzheng Dist.
Taipei
Taiwan
100
+886919932188
b9002009@cgmh.org.tw

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

Clinical application of drug screening in circulating tumor cells and exploring the impact of tumor microenvironment on the drug responses in patients with breast cancers

Study objectives

The prognostic value of circulating tumor cells (CTCs) is well established in breast cancer treatment, however, the drug screening of CTCs for therapeutic purposes remains to be explored. This study aims to investigate the clinical impact of CTCs in drug screening for the survival of patients with breast cancer.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 05/03/2020, Chang Gung Medical Foundation Institutional Review Board (199, Tung Hwa North Road, Taipei city, 10507, Taiwan; +886-3-3196200 #3703; irb1@cgmh.org.tw), ref: 202000120A3

Study design

Single-center prospective observational trial

Primary study design

Observational

Secondary study design

Case series

Study setting(s)

Hospital, Laboratory, Medical and other records

Study type(s)

Diagnostic, Treatment

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Clinical application of drug screening in circulating tumor cells in patients with breast cancers

Interventions

This study will investigate the clinical impact of circulating tumor cells (CTCs) in drug screening for the survival of patients with breast cancer. While the predictive value of CTCs is well established in breast cancer treatment, their role in drug screening for therapeutic purposes remains to be explored.

This study is a prospective observational cohort study involving a single study group, without an intervention or control group for comparison. Blood samples will be collected both before and after treatment for research purposes.

It is important to note that no intervention will be conducted throughout the study, and the results of the in vitro tests will not influence the treatment decisions for the patients. The study period will extend from enrollment to the end of medical data participation, encompassing the total duration of observation and follow-up.

Intervention Type

Other

Primary outcome measure

Correlation between anti-cancer drug tests and patient's clinical outcome measured using data collected from patient medical records as the evaluation of drug response between baseline and 3 to 6 months after treatment

Secondary outcome measures

The prognostic and predictive role of the count of circulating tumor cells (CTCs) measured using a fluorescence microscope to count CTCs and CTC-white blood cells (WBCs) at baseline, 3 to 6 months after treatment

Overall study start date

05/03/2020

Completion date

31/07/2023

Eligibility

Key inclusion criteria

Newly diagnosed primary locally advanced female breast cancer patients

Participant type(s)

Patient

Age group

Mixed

Lower age limit

18 Years

Upper age limit

80 Years

Sex

Female

Target number of participants

50

Total final enrolment

34

Key exclusion criteria

1. Participants undergoing primary surgery
2. Without informed consent

Date of first enrolment

05/03/2020

Date of final enrolment

31/07/2023

Locations

Countries of recruitment

Taiwan

Study participating centre

Chang Gung Memorial Hospital, Linkou

No.5, Fuxing St., Guishan Dist.

Taoyuan City

Taiwan

333

Sponsor information

Organisation

Linkou Chang Gung Memorial Hospital

Sponsor details

Department of Medical Research and Development, Chang Gung Medical Foundation

No.5, Fuxing St., Guishan Dist.

Taoyuan City

Taiwan

333

+886-3-3281200 #7675

a0643@cgmh.org.tw

Sponsor type

Hospital/treatment centre

Website

<https://www.cgmh.org.tw/eng>

ROR

<https://ror.org/02dnn6q67>

Funder(s)

Funder type

Charity

Funder Name

Chang Gung Medical Foundation

Alternative Name(s)**Funding Body Type**

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Taiwan

Results and Publications

Publication and dissemination plan

Planned publication in a peer-reviewed journal

Intention to publish date

31/08/2024

Individual participant data (IPD) sharing plan

The datasets generated during the current study will be published as a supplement to the results publication.

IPD sharing plan summary

Published as a supplement to the results publication